Translational research in neurology: dementia.
暂无分享,去创建一个
[1] Nick C Fox,et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.
[2] B. Gerton,et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. , 2012, Archives of neurology.
[3] B. Borroni,et al. Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease. , 2011, Mini reviews in medicinal chemistry.
[4] M. Weiner,et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.
[5] M. Weiner,et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia , 2011, Trends in Neurosciences.
[6] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[7] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[8] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[9] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[10] Paul M. Thompson,et al. Characterizing Alzheimer's disease using a hypometabolic convergence index , 2011, NeuroImage.
[11] R. Rosenberg,et al. DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation , 2011, Cellular and Molecular Neurobiology.
[12] D. G. Clark,et al. Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.
[13] Raymond Scott Turner,et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. , 2011, Archives of neurology.
[14] N. Herrmann,et al. Memantine in dementia: a review of the current evidence , 2011, Expert opinion on pharmacotherapy.
[15] M. Tuszynski,et al. Potential therapeutic uses of BDNF in neurological and psychiatric disorders , 2011, Nature Reviews Drug Discovery.
[16] Susan M Resnick,et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.
[17] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[18] K. Lunetta,et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.
[19] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[20] Arthur W Toga,et al. Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[21] C R Jack,et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.
[22] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[23] E. Siemers,et al. Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease , 2010, Clinical neuropharmacology.
[24] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[25] R. Green,et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.
[26] Nick C Fox,et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.
[27] N. Relkin,et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.
[28] Nick C. Fox,et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.
[29] S. Leurgans,et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.
[30] M. Rossor,et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial , 2009, The Lancet Neurology.
[31] Nick C Fox,et al. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.
[32] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[33] M. Wolfe,et al. Substrate-targeting γ-secretase modulators , 2008, Nature.
[34] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[35] A D Roses,et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.
[36] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[37] Robert A. Dean,et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.
[38] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[39] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[40] M. Citron. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.
[41] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[42] L. White. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. , 2009, Journal of Alzheimer's disease : JAD.
[43] D. Selkoe. Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. , 2008, Handbook of clinical neurology.